Literature DB >> 35017700

Retinal non-perfusion in diabetic retinopathy.

Charles C Wykoff1,2, Hannah J Yu3, Robert L Avery4, Justis P Ehlers5,6, Ramin Tadayoni7, SriniVas R Sadda8,9.   

Abstract

Diabetic retinopathy is a major cause of vision loss worldwide and areas of retinal non-perfusion (RNP) are a key pathologic feature of the vascular component of diabetic retinopathy. While there is a need for a more complete understanding of the natural history of RNP development and progression, overall, increasing RNP has been closely linked with worsening DR severity. Both traditional and novel approaches to quantitative image assessment are being explored to advance our understanding of the vascular, physiologic and functional changes associated with progressive RNP. Retinal ischemia secondary to RNP leads to tissue hypoxia and changes in the expression of a host of signalling molecules. Current anti-vascular endothelial growth factor and steroid pharmaceutical agents appear to be unable to reperuse areas of RNP, but may be able to slow the progressive longitudinal accumulation of RNP with regular retreatments. There remains a tremendous unmet need for pharmacotherapies that can slow RNP progression and ultimately reperfuse areas of the non-perfused retina. Towards this end, novel targets including the semaphorin family are being investigated.
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35017700      PMCID: PMC8807828          DOI: 10.1038/s41433-021-01649-0

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  39 in total

1.  The prognostic value of peripheral retinal nonperfusion in diabetic retinopathy using ultra-widefield fluorescein angiography.

Authors:  Fares Antaki; Razek Georges Coussa; Mikel Mikhail; Cyril Archambault; David E Lederer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-16       Impact factor: 3.117

2.  Distribution of capillary nonperfusion in early-stage diabetic retinopathy.

Authors:  T Niki; K Muraoka; K Shimizu
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

3.  DETECTION OF MICROVASCULAR CHANGES IN EYES OF PATIENTS WITH DIABETES BUT NOT CLINICAL DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Authors:  Talisa E de Carlo; Adam T Chin; Marco A Bonini Filho; Mehreen Adhi; Lauren Branchini; David A Salz; Caroline R Baumal; Courtney Crawford; Elias Reichel; Andre J Witkin; Jay S Duker; Nadia K Waheed
Journal:  Retina       Date:  2015-11       Impact factor: 4.256

4.  SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study.

Authors:  Wenying Fan; Akihito Uji; Kang Wang; Khalil Ghasemi Falavarjani; Charles C Wykoff; David M Brown; Jano Van Hemert; Min Sagong; Srinivas R Sadda; Michael Ip
Journal:  Retina       Date:  2020-06       Impact factor: 4.256

5.  Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography.

Authors:  Paolo S Silva; Amanda J Dela Cruz; Migil G Ledesma; Jano van Hemert; Ajlan Radwan; Jerry D Cavallerano; Lloyd M Aiello; Jennifer K Sun; Lloyd Paul Aiello
Journal:  Ophthalmology       Date:  2015-09-06       Impact factor: 12.079

6.  Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study.

Authors:  Wenying Fan; Kang Wang; Khalil Ghasemi Falavarjani; Min Sagong; Akihito Uji; Michael Ip; Charles C Wykoff; David M Brown; Jano van Hemert; SriniVas R Sadda
Journal:  Am J Ophthalmol       Date:  2017-06-01       Impact factor: 5.258

7.  Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.

Authors:  Rahul K Reddy; Dante J Pieramici; Shamika Gune; Avanti Ghanekar; Na Lu; Carlos Quezada-Ruiz; Caroline R Baumal
Journal:  Ophthalmology       Date:  2018-05-08       Impact factor: 12.079

8.  Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.

Authors:  Charles C Wykoff; Muneeswar G Nittala; Brenda Zhou; Wenying Fan; Swetha Bindu Velaga; Shaun I R Lampen; Alexander M Rusakevich; Justis P Ehlers; Amy Babiuch; David M Brown; Michael S Ip; SriniVas R Sadda
Journal:  Ophthalmol Retina       Date:  2019-07-24

9.  Quantitative Ultra-Widefield Angiography and Diabetic Retinopathy Severity: An Assessment of Panretinal Leakage Index, Ischemic Index and Microaneurysm Count.

Authors:  Justis P Ehlers; Alice C Jiang; Joseph D Boss; Ming Hu; Natalia Figueiredo; Amy Babiuch; Katherine Talcott; Sumit Sharma; Jenna Hach; Thuy Le; Alison Rogozinski; Leina Lunasco; Jamie L Reese; Sunil K Srivastava
Journal:  Ophthalmology       Date:  2019-06-08       Impact factor: 12.079

10.  Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study).

Authors:  Yoon Jeon Kim; Joon Hyung Yeo; Gisung Son; Hyojoo Kang; Yu Sub Sung; Joo Yong Lee; June-Gone Kim; Young Hee Yoon
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10
View more
  1 in total

1.  SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy.

Authors:  Huy Nguyen; Hui Chen; Meghah Vuppalapaty; Elizabeth Whisler; Kelsey Ronarda Logas; Parthasarathy Sampathkumar; Russell Byron Fletcher; Asmiti Sura; Nicholas Suen; Suhani Gupta; Tom Lopez; Jay Ye; Shengjiang Tu; Menaka Bolaki; Wen-Chen Yeh; Yang Li; Sung-Jin Lee
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.